CEL-SCI Corporation

NYSE AMEX: CVM

Geert Kersten Chief Executive Officer

8229 Boone Boulevard, Suite 802 Vienna, VA 22182, USA Phone: (703) 506-9460

Statements made during the course of this presentation that state the Company’s or management’s intentions, hopes, beliefs, expectations or predictions of the future are forward-looking statements. It is important to note that the Company’s actual results could differ materially from those projected in such forward-looking statements. This presentation only highlights some of the progress CEL-SCI has made to date. It is not meant to be a complete document as it forms only the visual basis of the company’s presentation. Additional information in general and concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained from time to time in the Company’s SEC filings, including but not limited to the Company’s report on Form 10-K for the year ended September 30, 2011. Copies of this presentation may be obtained by contacting the Company.

Forward-Looking Statements

2

Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized in this presentation involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled Phase III clinical trial of this investigational therapy that is currently in progress. Each page of this presentation must be looked at in the context of the whole presentation, not by itself, and is merely meant to be a summary of the full and detailed information on the Company in its public filings and its website. Potential conclusions could only be drawn if the initial observations in the early-phase studies relating to the potential adverse events associated with Multikine administration in treating head and neck cancer are confirmed in the well controlled Multikine Phase III clinical study, CEL-SCI's Phase III study is completed successfully, and the FDA licenses the product following their review of all of the data related to Multikine submitted in CEL-SCI's license application.

Explanatory Statement

3

• Name of Company: CEL-SCI Corporation

• Location: Washington, D.C. (USA) metro area

• Stock symbol: NYSE AMEX: CVM

• Shares outstanding: 230 million

• Current valuation: About $70 million

• Average daily trading volume, last 30 days: About 500,000

• 52 week range: $0.27 - $1.05

CEL-SCI Stock Summary

4

Product Pipeline

CANDIDATE PRECLINICAL PHASE I PHASE II PHASE III SALES

MULTIKINE

Head and Neck Cancer (first-line)

Cervical Cancer

Enhancement of radiation/chemotherapy

L.E.A.P.S. Technology

Pandemic Flu treatment

Rheumatoid Arthritis CEL-2000

Malaria

Viral Encephelities

Herpes

5

What is Multikine?

• Is an investigational immunotherapy drug consisting of 14 cytokines.

• Is being tested in a global Phase III clinical trial to determine its effectiveness against advanced primary head and neck cancer (US orphan drug status).

• Has a unique mechanism of action.

• Is given for 3 weeks BEFORE any other cancer therapies (surgery, radiation and/or chemotherapy) because that would appear to be the best time to produce an effective immune response.

• Teva Pharmaceuticals (Israel) and Orient Europharma (Taiwan) are partners and participate in the Phase III trial.

• Multikine, once approved for sale, would be mass produced in the Company’s existing manufacturing plant.

• Multikine uses the patient’s own tumor antigens to provide specificity for the anti-tumor immune response.

• The primary focus of Multikine is to eliminate the micro-metastases, believed to be the cause of cancer recurrence.

Summary of ”What is Multikine”

6

Multikine Cancer Immunotherapy

Multikine represents the next class of generation immunotherapy drugs because:

1) Multikine is given before any other cancer therapy – optimal time, biggest market.

2) Multikine contains both active and passive immunity and therefore does not require an outside antigen.

3) Multikine is mass produced at the Company’s manufacturing facility. It is NOT made from the patient’s own blood and/or tumor – reasonable price with excellent profit margin.

Next Class of Immunotherapy Drugs

7

Multikine Cancer Immunotherapy

Clinical Development of Multikine

• Locally advanced primary head & neck cancer patients • Current standard of care as defined by the NCCN Clinical Practice Guidelines

in Oncology, Head and Neck Cancer, is: Surgery followed by Radiation Therapy (+/- Chemo)

• Upon the success of the Multikine Phase III study and approval by the FDA and other regulatory agencies, one would expect that doctors will elect to give Multikine to head and neck cancer patients ahead of surgery.

Multikine Treatment Surgery Radiation Therapy (+/- Chemo)

8

Multikine – Lead Indication is First-Line H&N Cancer

Head and neck cancer:

6% of all cancers, or about 650,000 new cases annually worldwide, 150,000 of those are in the US and EU. About 2/3 of these head and neck cancer patients have advanced primary disease.

• Unmet medical need.

• Uniform standard of care world-wide for advanced primary head and neck cancer.

• Approval could potentially lead to Multikine becoming part of the standard of care treatment along with the first treatment of surgery, radiation and chemo (first line standard of care).

• Multi-billion $ market opportunity.

• Likelihood of world-wide approval on successful single Phase III study.

Initial target market

9

“Proof of Concept” Phase II Results

• Summary of “Proof of Concept” Phase II results using the same treatment schedule as is being used in Phase III study

Multiple studies were conducted to select the final treatment regimen

Improvement in overall survival at 3.5 years (J. Oral Oncology; n=19) Long term survival in Multikine treated group (n=19) was 63.2% Long term survival of all patients in literature (n=7,294) was 47.5% No Severe Adverse Events related to Multikine (All Phase I/II Studies to date:

n=220) No deaths related to Multikine (All Phase I/II Studies to date: n=220) Phase I/II studies conducted in US, Canada, Europe and Israel Impact of Multikine (after 3 week treatment, PRIOR to surgery) 12% of the patients had no tumor after only Multikine treatment (by pathology)

(ASCO and Journal of Clinical Oncology; MK Treated n=19: 17 SCC; CR 2, PR 4 by RECIST)

50% reduction in the number of tumor cells after only Multikine treatment (by pathology) (Journal of Clinical Oncology; n=19)

Additional and confirmatory survival, pathology and tumor response data published in:

– Archives of Otolaryngology August 2003 (Feinmesser et al) (n=12) – The Laryngoscope Dec. 2003 (Timar et al) (n=54)

Multikine

10

Phase I-II Safety Profile

• In safety and dose finding studies:

During the early investigational phase, in Phase I and Phase II clinical trials in a total of over 220 subjects who received the investigational therapy Multikine in daily doses of 200 to 3200 IU as IL-2 (over 2-3 weeks in Phase II and up to a few months in early-Phase I), no serious adverse events were reported by the clinical investigators as being expressly due to administration of this investigational therapy Multikine. Adverse events which were reported included pain at the injection site, local minor bleeding and edema at the injection site, diarrhea, headache, nausea, and constipation. No "abnormal" laboratory results were reported following Multikine treatment - other than those commonly seen by treating physicians in this patient population - regardless of Multikine administration. Similarly, in these early-phase clinical studies in patients, there was no reported increased toxicity of follow-on treatments as a result of Multikine administration. No complications following surgery (such as increased time for wound healing) were reported.

Multikine Clinical Development

11

Multikine

Histological appearance of necrosis in Oral Squamous Cell Carcinoma (OSCC) [HE staining]:

Non-Multikine treated Multikine treated

Non-Multikine treated: Lack of necrosis in the epithelial nests of OSCC Multikine treated: Entire cancer nest is necrotic and filled with debris and leukocytes

This complete destruction of the tumor was seen in only 12% of the patients

Oral Squamous Cell Carcinoma

(Locally Advanced Primary H&N Cancer)

Multikine Potential Treatment Effect – Changes in Tumor Microenvironment

12 * Modified from Timar et al., Journal of Clinical Oncology 23(15) May 20, 2005

Source: Timar et al., Journal of Clinical Oncology 23(15) May 20, 2005

Multikine

Lymphoproliferative (e.g., IL-2)

Antigen Presenting Cells (Dendritic Cells, Macrophages)

Neutrophils

CD4 + T Cells

Tumoricidal / Tumoristatic

Necrosis (e.g., TNF)

Multikine (peritumoral)

Chemotactic (e.g., IL-6, IL-8)

Tumor

Lymph

Nodes

Local / Regional

Multikine (perilymphatic)

Micro Metastases

CD8 + T Cell Micro

Metastases

Mechanism of action

13

* Talor et al., ASCO Annual Meeting Proceedings 22(14S): 189S, 2004 Timar et al., Journal of Clinical Oncology 23(15) May 20, 2005

CD4/CD8 < 0.5

Control (n=20)

CD4/CD8 > 2.5

MK Treated (n=17)

[+2 CR]

A Paradigm Shift in Tumor Microenvironment

Multikine Treatment Effect on Host CD4 and CD8 Tumor Infiltrating Cell Density in OSCC

(Locally Advanced Primary H&N Cancer)

Multikine Treatment Effect

14

Density of cells/HPF (Mean ± SEM)

0 50 100 150

CD4

P<0.05

P<0.05

CD4 Control

MK Treated

CD8

CD8

How Multikine circumvents the tumor defense mechanisms!

CD8+ T-cells and NK cells not treated with Multikine are “blocked” by the tumor. Therefore they are unable to trigger a potential anti-tumor immune response.

CD8

CTL

LYMPH

NODE

T cells

T

cells

DC

DC

NK

Cells

Class I

NKR

Inhibition

Class I

Tumor

Class II

No Activation

?

No potential anti-tumor response

No potential anti-tumor response

Multikine

15

CD8

CTL

LYMPH

NODE

T cells

T

cells

DC

DC

NK

Cells

Class I

NKR

Class I

Tumor

Class II

No Activation

?

No potential anti- tumor response

(Activated)

Help (Including MIP-1α)

CD4 (Activated)

TCR

IL-2,

IFN-γ

IL-2, IFN-γ

How Multikine circumvents the tumor defense mechanisms! Following Multikine administration tumor-specific activated CD4+ helper T cells “rescue” and activate tumor residing NK cells, which then trigger a potential

anti-tumor response.

Multikine

16

• Advanced primary (not yet treated) head & neck cancer represents an unmet medical need (about 50% of the patients die within 3 years following treatment) with minimal progress over the last 50 years.

• FDA, Canadian and seven other regulators on three continents gave go-ahead to Multikine Phase III study.

• Effort was led by CEL-SCI’s Senior VP of Regulatory Affairs, John Cipriano, MS, RPh, who was the prior Deputy Director, Division of Biologics Investigational New Drugs, Office of Biologics Research and Review at the FDA.

• Orphan drug designation in the US codifies that only one trial should be needed.

Multikine: Phase III trial

One pivotal Phase III trial

17

• USA, Canada, Hungary, Poland, Russia, Israel, India and Taiwan. Started the study in all 8 countries to date.

• Planned enrollment: 880 patients.

• To date, 36 centers have passed SIV and are screening/accruing patients; goal is to reach about 50 centers in total.

• Partners in Phase III study:

Israel - Teva Pharmaceuticals.

Taiwan- Orient Europharma of Taiwan.

• Primary endpoint = 10% improvement in overall survival.

• Event-driven study.

• NIH participation for measurement of genetic and molecular markers of patients.

Multikine Phase III trial

Phase III Trial

18

Methodology:

• Phase III open-label, randomized, controlled, multi-center study.

Enroll about 880 patients to have about 780 evaluable patients.

Reference Therapy: Standard of Care = Surgery + Radiation +/- Chemotherapy.

Three (3) week administration of Multikine + standard of care and median three year follow-up (event–driven).

Primary end point: Overall Survival.

Statistics:

• 80% Power; 95% confidence - to show a 10% Overall Survival advantage.

Multikine: Phase III trial

Study Design and Statistical Parameters

19

Multikine Phase III Schematic Randomization and Treatment of Enrolled Patients

The overall survival comparison will be made between groups 1 and 2. The primary purpose of the

smaller Group 3 is to gain more information on the mechanism of action of Multikine. CIZ is added to

decrease tumor suppressor mechanisms and thereby increase Multikine effectiveness.

* CIZ: Cyclophosphamide 300 mg/m2 (x1,IV, day -3); Indomethacin 25mg tid, po (day 1 to 24 hrs prior to surgery) + 15-45mg Zinc (as Multivitamin) i.d., p.o.

** Surgery: complete surgical resection of primary tumor and any positive lymph nodes.

*** High risk patients are defined as those with: positive surgical margins, 2 or more

clinically positive nodes, or extra capsular nodal spread (any or all of the above).

E

N

R

O

L

L

R

A

N

D

O

M

I

Z

E

Group 1 (approx. 377 pat.)

Standard of Care

Group 3 (approx. 125 pat.)

Multikine 5X/week for 3 weeks

(No CIZ)

S**

U

R

G

E

R

Y

RTx

Radiotherapy (60 - 70 Gy,

30 - 35 fractions over 6 - 7 Weeks)

-OR-

CRTx

*** High Risk: Concurrent

radiochemotherapy (60 – 70) Gy, 30 - 35

fractions, over 6-7 weeks + IV cisplatin

(Dose 100 mg/m2) 1X per week on first

day of weeks 1, 4, 7 of RTx

Group 2 (approx. 377 pat.)

Multikine 5X/week for 3 weeks

(+ CIZ*)

3

1

3

CIZ Arm - CIZ included to enhance Multikine activity

• Cyclophosphamide - low (non-chemotherapeutic) dose decreases tumor suppressor cells (Berd Cancer Res. 1984, 1986; North J. Exp. Med 1982; Kameda Int. J. Immunother. 1992; Timar JCO 2005)

• Indomethacin - Low dose indomethacin retards the secretion of

prostaglandin E-2 (PGE-2) by tumor residing monocytes/macrophages a potent inhibitor of lymphocyte proliferation (Feinmesser Arch Otolaryngol H&N Surg 2003).

• Zinc - known to increase activation of thymus factors associated with

increased T cell activity. Non-CIZ Arm – Included to attempt to determine the extent of the contribution of

CIZ to Multikine effects.

Multikine Phase III trial

21

Purpose of Multikine + CIZ and Multikine without CIZ study arms

• World-wide: Eight countries on three continents: North America, Europe, Asia.

• Largest pathology study ever done in head and neck cancer.

• Partners enrolling in the study:

Israel - Teva Pharmaceuticals.

Taiwan- Orient Europharma of Taiwan.

• Subjects enrolled in approximate proportion to world distribution of the disease.

• Expect rapid enrollment and relatively fast results.

• NIH participation for measurement of genetic and molecular markers of patients (personalized medicine).

Multikine Phase III trial

Large Phase III Study Designed To Position Multikine As Part of the Standard of Care

22

Attention to detail is key:

• Radiation qualifications conducted by RPC (MD Anderson Cancer Center, The University of Texas).

• Central Imaging qualifications conducted by a leading US company specializing in Clinical Trial Imaging.

• Central Pathology Laboratory.

• All study drugs (e.g. chemotherapy) are sourced from same place only.

• Cold shipping around the world provided by leading US company with fully validated containers.

Multikine Phase III trial

Preparation and Management of Large Global Phase III Trial

23

Patents and other protection for Multikine:

• Composition of matter patent protection until 2024.

• US Patent # 6,896,879 and European Patent # 1,773,395.

• Additional pending patent applications world-wide. • Orphan drug designation in US gives 7 year market exclusivity.

• Proprietary manufacturing and quality control know-how (most important

since Multikine is a complex biologic and practically impossible to copy).

Multikine IP

Intellectual property protection

24

• Commercial sized $25 million manufacturing facility outside Baltimore, Maryland, USA.

• Facility includes True Cold Fill (+4°C) capability to avoid loss of biological activity during fill.

• Successful EU Audit in Fall 2010:

CEL-SCI Corporation's Manufacturing and Laboratory Operations Deemed Compliant with GMP Requirements Following Audit by European Union Qualified Person.

• Facility will supply Phase III study and subsequent commercial sale.

Current capacity about 20,000 treatments annually.

Fully built out capacity about 60,000 treatments annually.

Steps to improve risk/reward

25

Multikine Manufacture

Retain head and neck cancer indication rights for the US and Europe, offering shareholders the full upside potential.

Additional partnerships are anticipated outside of US/EU and for other tumor indications.

CEL-SCI’s current partners funding and participating in Phase III trial:

• Teva Pharmaceuticals of Israel (Territories: Israel and Turkey, added Serbia and Croatia in summer of 2011).

Teva will run and pay for part of the Phase III trial in Israel. Revenue share upon sale.

• Orient EuroPharma (OEP) of Taiwan (Territories: parts of the Far East, not Japan or China).

OEP will run and pay for part of the Phase III trial in Taiwan. Revenue share upon sale.

Multikine Phase III partners

26

Steps to improve shareholder reward/risk prospects

Maximilian de Clara • Founder, President and Chairman of the Board, CEL-SCI Corporation, 1983 - Present • Personally funded research in the fields of biotechnology and biomedicine • Awarded the "Pour le Merit" honorary medal of the Austrian Military Order

"Merito Navale" • Awarded the Honor Cross of the Austrian Albert Schweitzer Society

Geert Kersten, MBA, JD • Chief Executive Officer, CEL-SCI Corporation, 1987 – Present

Patricia B. Prichep • Senior Vice President of Operations, CEL-SCI Corporation, 1992 – Present • Manager, Quality and Productivity, National Association of Securities

Dealers (NASD), Rockville, MD, 1989 - 1992

Key Management Team

27

Business

Eyal Talor, PhD • Chief Scientific Officer 2010 – Present • Senior Vice President of Research and Manufacturing, CEL-SCI Corporation,

1994 – Present • Director of R&D and Clinical Development, CBL, Inc., Baltimore, MD • Principal Scientist - Project Director, Clinical Laboratory Director, SRA

Technologies, Inc. • Adjunct Professor at Johns Hopkins University Medical Institutions

John Cipriano, MS, RPh

• Senior Vice President of Regulatory Affairs, CEL-SCI Corporation • Deputy Director, Division of Biologics Investigational New Drugs, Office of

Biologics Research and Review, Food and Drug Administration (FDA) • Deputy Director, IND Branch, Division of Biologics Evaluation, Office of

Biologics, Food and Drug Administration (FDA)

Daniel Zimmerman, PhD • Senior Vice President of Research, Cellular Immunology, CEL-SCI

Corporation • L.E.A.P.S. Technology Inventor • Founder and President, CELL-MED, Inc., 1987 – 1995 • Scientist, Sr. Scientist, Technical Director and Program Manager,

Electronucleonics, Inc., 1973 – 1987

Key Management Team

28

Science

William “Brooke” Jones • Vice President of Quality Assurance, CEL-SCI Corporation, 1999 – Present • Director of Quality Control and Quality Assurance at the Systemix Facility in

Lyon, France, 1994 - 1997 • Management positions at Biogen, 1983 - 1991 • Head of GMP Compliance at Fort Detrick, NCI- Frederick Cancer Research

Center, 1979 - 1983 Todd Burkhart

• Vice President of Manufacturing/Facilities & Commercial Operations, CEL-SCI Corporation, 2010 – Present • 30 years of experience in the manufacture and process development of

biologics, medical devices and other Active Pharmaceutical Ingredients (APIs)

• Previously ran a number of major pharmaceutical facilities at companies such as Cephalon, Human Genome Sciences and Univax Biologics

Key Management Team

29

Science

Thank You